Shots: The US FDA has granted FT designation to NVX-CoV2373 which is currently in late-phase clinical development. Novavax expects to initiate pivotal P-III study in the US & Mexico by the end of Nov’2020 The company’s ongoing P-lll trial in the UK to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 is expected to be […]Read More
Shots: Novavax will supply ~60M doses of its COVID-19 vaccine to the UK government for P-III study evaluating the efficacy of NVX-CoV2373 in ~9,000 adults aged 18-85yrs. in the UK. The trial is expected to initiate in Q3’20 Novavax will expand its collaboration with FUJIFILM Diosynth, which will manufacture the antigen component of NVX-CoV2373 from […]Read More
Shots: SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product SK bioscience will utilize its cell culture and recombinant protein capability, will initiate the production of the NVX-CoV2373 antigen at […]Read More
Shots: Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to be initiated in mid-May with its preliminary immunogenicity and safety results in July The study will be the third confirmed global COVID-19 vaccine trial and […]Read More
Shots: Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. Novavax will integrate its Matrix-M adjuvant with NVX-CoV2373 to improve the immune response stimulates high levels of neutralizing Ab The company plans to combine P-I/II […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
